Anergis SA
BiopĂ´le  III
Route de la Corniche 9B
CH-1066 Epalinges
Tel: +41- 21 651 92 20
Fax: +41 21 651 92 21

Welcome to Anergis



Anergis is a clinical-stage biopharmaceutical company based in Switzerland.

Anergis is focused on the development of a high potential product pipeline of fast acting immunotherapeutics, providing a beneficial disease-modifying effect to patients with moderate to severe allergies.

Anergis allergy immunotherapeutics are derived from Anergis' proprietary long peptide technology platform using synthetic, pharmaceutical-grade Contiguous Overlapping Peptide ("COP"). COPs are peptides of 40-80 amino-acids which are safer (no risk of immediate allergic reaction) and can elicit a faster immune response than the allergenic proteins they are derived from.

As a result, treatment with a COP allergy immunotherapeutic requires only a single course of 2 months of treatment, instead of 3 to 5 years with currently marketed subcutaneous or sublingual allergy immunotherapy products.


Ultra-fast allergy immunotherapy will represent a very significant progress in the treatment of allergic patients by providing dramatically improved acceptance and compliance rates to allergy immunotherapy (AIT), in comparison with currently marketed AIT approaches.

If you are interested to participate in one of our clinical trials, please send an email to


04 June 2015
Anergis to Present Three Scientific Posters at 34th European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015

02 June 2015
Anergis Appoints Kim Simonsen as Chief Development Officer

01 April 2015
Anergis Announces Completion of Treatment in AllerT Phase II Dose-Ranging Trial

23 February 2015
Anergis Presents Sustained Efficacy Data from its AllerT Phase IIb Trial at the AAAAI Annual Meeting

23 February 2015
Abstracts of Anergis Communications at AAAAI Houston - 2015.02.22

19 December 2014
Anergis Granted U.S. Patent for Ragweed Allergy Vaccine AllerR

see details